A Case of Pityriasis Rosea Following Monkeypox Vaccination
Main Article Content
Keywords
Pityriasis Rosea, Monkeypox, Vaccine
Abstract
Introduction: Pityriasis rosea (PR) is a well-known but uncommon, benign papulosquamous skin condition that often occurs after viral infections or vaccinations. The most commonly implicated vaccine is smallpox. Monkeypox (MPX), a related virus to smallpox within the orthopox family, has recently grown in public health concern. We present here a case of PR following MPX vaccination in an African-American man.
Case Report: A 32-year old African-American man presented for evaluation of a one-month history of rash that first appeared as an isolated itching spot on his right mid-back, followed by papular eruptions on his trunk with extremity sparing. He denied recent illnesses, medication use including NSAIDs, or history of similar rash. He did report receiving his first MPX dose about one week prior to rash onset. Pityriasis rosea was diagnosed based on clinical presentation and suspected secondary to the patient’s MPX vaccine course.
Conclusion: There are currently two available vaccines for MPX protection in the United States, both of which are vaccinia-based and developmentally related to the smallpox vaccine. Given the known association of smallpox and PR, PR reactions following MPX vaccination may occur.
References
2. Leung AKC, Lam JM, Leong KF, Hon KL. Pityriasis Rosea: An Updated Review. Curr Pediatr Rev. 2021;17(3):201-211. doi:10.2174/1573396316666200923161330
3. Simpson K, Heymann D, Brown CS, et al. Human monkeypox - After 40 years, an unintended consequence of smallpox eradication. Vaccine. 2020;38(33):5077-5081. doi:10.1016/j.vaccine.2020.04.062
4. Bunge EM, Hoet B, Chen L, et al. The changing epidemiology of human monkeypox-A potential threat? A systematic review. PLoS Negl Trop Dis. 2022;16(2):e0010141. doi:10.1371/journal.pntd.0010141
5. Drago F, Ciccarese G, Javor S, Parodi A. Vaccine-induced pityriasis rosea and pityriasis rosea-like eruptions: a review of the literature. J Eur Acad Dermatology Venereol. 2016;30(3):544-545. doi:10.1111/jdv.12942
6. Rao AK, Petersen BW, Whitehill F, et al. Use of JYNNEOS (Smallpox and Monkeypox Vaccine, Live, Nonreplicating) for Preexposure Vaccination of Persons at Risk for Occupational Exposure to Orthopoxviruses: Recommendations of the Advisory Committee on Immunization Practices — United States, 2022. Morb Mortal Wkly Rep. 2022;71(22):734–742. doi:10.15585/mmwr.mm7122e1
7. Volz A, Sutter G. Modified Vaccinia Virus Ankara. Adv Virus Res. 2017;97:187–243. doi:10.1016/bs.aivir.2016.07.001
8. Islam R, Hossain J, Roy A, et al. Repositioning potentials of smallpox vaccines and antiviral agents in monkeypox outbreak: A rapid review on comparative benefits and risks. Heal Sci Reports. 2022;5(5):e798. doi:10.1002/hsr2.798
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation.
Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.
Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.